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Tublication bias, manifested most prominently by lack of
ublication of negative results, has been an increasing source
f concern for the past several years. In fact, in 2000 Song
t al. (1) published a 120-page monograph devoted entirely
o publications bias from the Health Technology Assess-
ent Program of the National Health Service. The issue
ame to a head recently when Glaxco was sued for with-
olding results from clinical trials showing a lack of efficacy
nd potential increase of suicidal thoughts among adoles-
ents on the antidepressant Paxil. The firm paid a fine and
greed to publish both the protocols and results of the
linical studies of its drugs in an open registry. Soon
hereafter, a group of editors announced that they would no
onger publish clinical trials whose protocols had not pre-
iously been placed in a public registry (2). These events
ave raised a number of questions: What constitutes pub-
ication bias? How prevalent is it and what effect does it
ave? And most importantly here, what is the role of
ournals in solving the problem?
The initial observation of publication bias dates to 1959
hen Sterling (3) found that 97% of articles in four journals
eported statistically significant findings, raising the likeli-
ood that studies lacking significant differences were not
eing published. Primary attention has since focused upon
nreported clinical studies with negative results, often re-
erred to as “the file-drawer problem.” Concern has recently
een extended to incomplete publications that fail to present
ll the studies undertaken and/or results available. In fact, a
ecent study found that of 102 randomized trials examined,
0% of efficacy data and 65% of adverse effects were
ncompletely reported (4). The definition of publication bias
as been further expanded to encompass dissemination bias,
r the accessibility to research findings related to when,
here, and in what format the findings are published. Thus,
tudies whose publication is delayed, or appears in non-
ndexed journals or uncommon languages, or is ignored by
he media, may also be considered to suffer publication bias.
he common denominator, of course, is the failure to bring
ata of potential importance to the attention of physicians
nd the public.
The possible consequences of publication bias are also fairly
bvious. Of greatest importance is the misrepresentation of the
fficacy or adverse effects of a diagnostic or therapeutic modal-
ty. Unreported adverse effects are, of course, the most danger-
us possible consequence. Current guideline recommendations
re usually based upon at least two publications with concor- cant results. If only two of three or four completed studies are
ositive, and only those results are reported, one obviously gets
distorted view of the efficacy of the intervention. We live in
n era where meta-analysis of multiple small trials is often
equired to assess significance and efficacy. Clearly, meta-
nalysis will be extremely flawed if all available data are not
aken into consideration. Unreported clinical studies represent
asted resources, and may result in other investigators under-
aking the same futile experiment. Finally, failure to publish
esults is unfair to the patients who have voluntarily partici-
ated at some possible inconvenience, discomfort, and risk.
here can be no doubt that publication bias is a serious
roblem for medicine.
The responsibility for publication bias can be attributed to
ultiple sources. Investigators bear a major responsibility,
ecause publication must begin with them. There is little
uestion that negative results stimulate less enthusiasm for the
nalysis and manuscript preparation required for peer-review
ublication than positive findings. My experience has con-
rmed that reviewers generally share in the lack of enthusiasm
or negative results. In fact, most editors are likely inclined to
iew negative findings less favorably because we are seeking to
ublish findings that will alter medical practice. When prior-
tizing limited pages, it is only too easy to downgrade a study
which just shows negative findings.” The media and authors
f review articles are also less likely to feature negative trials.
e at JACC are often counseled not to accept reports of
nsuccessful interventions since “they will disappear on their
wn.”
Finally, the role of the medical industry must be consid-
red. The incentives inherent in the profit motive are so
ntuitive that suspicion nearly always exists regarding the
otential of industry to suppress negative results. In fact,
vidence of such behavior does exist. However, in my
pinion, the role of industry in contributing to publication
ias is less, overall, than that of the other sources.
As in so many controversial areas of medicine, precise
ata regarding the prevalence and actual effects of publica-
ion bias are lacking. The literature is replete with direct or
ndirect evidence of bias in virtually every area of medicine;
t almost seems that if you look for it, you will find it.
owever, the true magnitude of the problem remains
ndefined (1). (It should be noted that articles on publica-
ion bias are susceptible to such discrimination themselves.
hat is, papers seeking to report the failure to find publi-ation bias may face a lesser chance of being submitted and
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Editor’s Page October 19, 2004:1707–8ccepted for publication.) Similarly, it is difficult to measure
he effect of publication bias upon clinical care and patient
utcome. In most cases, interventions that fail in clinical
rials are abandoned. However, the absence of quantitative
ata regarding the effects of publication bias should not
iminish the importance of the problem.
Given the various sources responsible for publication bias,
t is clear that no single action will eliminate the problem.
fforts should be made, using either a carrot or a stick, to
ave investigators prepare and submit manuscripts describ-
ng the complete results of clinical studies. Given the need
o publish for academic advancement, one would think that
his should be easy. Removing any external inhibition
rising from sponsors and journals would definitely be of
alue. Likewise, non–peer-review medical media should be
ncouraged to disseminate and extol the contribution of
egative clinical studies. This may be more difficult to
mplement as negative studies are often, de facto, less
nteresting.
Despite the value of these measures, the focus of atten-
ion has clearly turned to medical journals to rectify the
roblem of publication bias. It has been recommended that
ditors not only remove any references to the desirability of
ignificant findings from their instructions to authors, but
roactively encourage submission of clinical studies that fail
o reach significance. Editors could minimize publication
ias by being especially observant in the selection of review-
rs and consideration of their critiques. It has even been
dvocated that journals extend a provisional acceptance for
ublication based upon the rigor of a research protocol.
ickard Horton of Lancet has done this for some time, with
he rationale that a well-designed protocol will yield useful
esults whether they are positive or negative.
The intervention to overcome bias that has been most
romoted has been universal registration of clinical studies.
uch registration would place the trial in the public domain
nd would not only include the rationale, methods, inves-
igators, and sponsors, but ultimately the results. It has been
rgued that the best way to achieve such a registry would be
or journals to require registration at enrollment to qualify
or publication. Presumably, no investigator would risk
aving the results of a trial go unreported for lack of
egistration.
To implement this strategy, the International Committee
f Medical Journal Editors (ICMJE), comprising 10 general
edical journals worldwide, published editorials stating that
rom July 2005 on they would require, as a condition for
ublication, registration in a public trials registry at the start
f the enrollment. The registry must be accessible to the
ublic at no charge, electronically searchable, have a mech-
nism for data validation, and be managed by a not-for-
rofit organization. The editors specifically mentioned the
linical trials registry sponsored by the U.S. National Li-
rary of Medicine. Although these editors spoke for them-elves, they urged all other journals to join them in this
olicy.
I must admit that I have somewhat mixed feelings about
his proposal. There is no question in my mind that
ublication bias is a significant problem and must be
ddressed. I also agree that medical journals have some
nique abilities to bring to bear on this problem. Therefore,
certainly do not object to having JACC adopt the require-
ent for clinical trials registration advocated by the ICMJE.
owever, while this action may be of value in managing
ublication bias, it will neither eliminate it nor is it
ecessarily the appropriate function for a journal. To begin
ith, registration alone will not ensure submission and
ublication of results nor convey the credibility of peer
eview. Neither will this action foster dissemination of the
esults when the trial is completed. Journals have significant
age limitations, at least with regards to print, and existing
ournals could not likely accommodate every clinical trial in
urrent pages. Moreover, an important function of journals
s to prioritize the most newsworthy information for its
eaders, findings which will change behavior, so that they
an devote available reading time most efficiently. This
rioritization is clearly one of the attractions of each journal,
nd editors will likely be reluctant to compromise it.
Finally, I wonder if it is an appropriate role for a journal
o be a policeman. The job of editors is to bring important
ew information to readers as soon as possible, not to
dminister punitive measures to investigators who do not
dhere to standards for research. If in the course of an
nregistered (for any reason) clinical trial the investigators
tumbled on a very important finding, would editors really
efuse to publish that finding? And if so, would society
enefit? It seems to me that to require trial registration to
ualify for publication is at best an imperfect attempt to
ddress unreported study results, and one that uses journals
or a purpose for which they were not intended. Neverthe-
ess, until a better, more comprehensive solution to publi-
ation bias comes along, JACC will try to observe the
egistration requirement. Just as in politics, the best thing
bout some options is the alternative.
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ACC, Editor-in-Chief, Journal of the American College of Car-
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